Interleukin 35: protective role and mechanism in type 1 diabetes

Zhang, Si-Ming; Liang, Jun; Xia, Jun; Li, Li; Li, Zheng; Wang, Yalan; Li, Yanhong; Li, Yan; Lu, Y. P.

doi:10.5114/ceji.2023.125043

Cited by 4 publications

(3 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IL-35 has gained signi cant attention in recent years as a potential key regulator of diabetes, particularly chronic in ammatory type 1 and autoimmune diabetes, which are increasingly affecting children and teenagers across different regions worldwide [1][2]. Studies suggest that IL-35 can offer protection against type-1 diabetes and autoimmune diabetes by regulating macrophage polarization, Tcell-related cytokines, and regulatory B cells (Bregs) [3]. The development and progression of autoimmune diabetes or T1D can be in uenced by various cytokines produced by both immune and pancreatic cells.…”

Section: Full Textmentioning

confidence: 99%

Interleukin-35: A key player in chronic inflammatory Type 1 and autoimmune diabetes

Bala,

Chakraborty,

Mukherjee

2024

Preprint

View full text Add to dashboard Cite

Interleukin-35 (IL-35) is a protein that was recently discovered and is composed of IL-12α and IL-27β chains. It is produced by the IL12A and EBI3 genes. Interest in the study of IL-35 has grown significantly in recent years, as evidenced by numerous scientific publications. Clinical research has revealed that patients who are negative for C-peptide have significantly lower serum levels of IL-35, which is accompanied by a decrease in the proportion of IL-35+ Treg cells, regulatory B cells, and CD8+ FOXP3+ cells that produce IL-35. This article highlights the potential importance of IL-35 expression in regulating the immune response and its role in chronic inflammatory Type 1 and autoimmune diabetes in the context of pancreatic inflammation, including its ability to control cytokine proportions, regulate B cells, and provide protection against autoimmune diabetes. Nonetheless, additional research is required to determine the exact mechanism of IL-35, and clinical trials must be carefully planned.

show abstract

Section: Full Textmentioning

confidence: 99%

Interleukin-35: A key player in chronic inflammatory Type 1 and autoimmune diabetes

Bala,

Chakraborty,

Mukherjee

2024

Preprint

View full text Add to dashboard Cite

show abstract

“…IL-35 is a more recently discovered member of the interleukin 12 family, primarily produced by Tregs [17]. It has strong immunosuppressive properties, and its overexpression in cancer correlates with poor prognosis [18].…”

Section: Cytokines/chemokinesmentioning

confidence: 99%

The Role of Regulatory T cells (Tregs) in Tumorigenesis: A Comprehensive Literature Review

Torabiardakani

2024

URNCST Journal

View full text Add to dashboard Cite

Introduction: Regulatory T cells (Tregs) are a subpopulation of CD4+ T lymphocytes that contribute to immune homeostasis by suppressing excessive immune activation. However, these immunosuppressive properties can lead to the suppression of anti-tumor immune responses. Depletion or blocking of Tregs through therapeutics has emerged as a possible method for enhancing anti-tumor immunity. However, the lack of selective targeting of Tregs in the tumor microenvironment is a significant limitation to the effectiveness of Treg therapies. Therefore, this investigation aims to review current literature on how Tregs suppress the antitumor immune response and how they can be targeted to promote anti-tumor immunity. Methods: This review examines recent literature on Tregs in the tumor microenvironment, focusing on both cell-contact dependent and independent mechanisms. Clinical trial studies were also included to assess therapeutic targeting of Tregs. The PubMed database was systematically searched for English articles from 2010 to present, supplemented by manual searches without date restrictions. Boolean expressions ensured comprehensive study retrieval. Results: The involvement of Tregs in the development of multiple cancer types is evident, and targeting these cells could potentially enhance the efficacy of antitumor immunity. In addition, we compiled a list of the novel approaches currently being used for Treg targeting in the context of cancer. Discussion: This review has identified the most promising targets for Treg-based therapies, opening avenues for accelerating the development of innovative cancer treatments. Conclusion: Our literature review offers insights into the complex interplay between the immune system and cancer. The understanding of this interaction is not just an endpoint but could potentially act as a steppingstone towards new scientific discoveries.

show abstract

“…Studies have implicated that interleukin-35 (IL-35), a known anti-inflammatory cytokine in the IL-12 family, improves glycemic control and protects against DM1 by regulating the polarization of macrophages and the proportion of T cell-related cytokines [5,6]. IL-35 is not found in all human tissues, but may be induced in response to inflammatory cytokines [7].…”

Section: Introductionmentioning

confidence: 99%

The Relationship between TNF-a, IL-35, VEGF and Cutaneous Microvascular Dysfunction in Young Patients with Uncomplicated Type 1 Diabetes

Neubauer-Geryk,

Wielicka,

Myśliwiec

et al. 2023

Biomedicines

View full text Add to dashboard Cite

The aim of this study was to analyze the relationship between immunological markers and the dysfunction of cutaneous microcirculation in young patients with type 1 diabetes. The study group consisted of 46 young patients with type 1 diabetes and no associated complications. Microvascular function was assessed with the use of nail fold capillaroscopy before and after implementing post-occlusive reactive hyperemia. This evaluation was then repeated after 12 months. Patients were divided into two subgroups according to their baseline median coverage (defined as the ratio of capillary surface area to surface area of the image area), which was established during the initial exam (coverageBASE). Additionally, the levels of several serum biomarkers, including VEGF, TNF-a and IL-35, were assessed at the time of the initial examination. HbA1c levels obtained at baseline and after a 12-month interval were also obtained. Mean HbA1c levels obtained during the first two years of the course of the disease were also analyzed. Patients with coverageBASE below 16.85% were found to have higher levels of VEGF and TNF-α, as well as higher levels of HbA1c during the first two years following diabetes diagnosis. Our results support the hypothesis that the development of diabetic complications is strongly influenced by metabolic memory and an imbalance of pro- and anti-inflammatory cytokines, regardless of achieving adequate glycemic control.

show abstract

Interleukin 35: protective role and mechanism in type 1 diabetes

Cited by 4 publications

References 39 publications

Interleukin-35: A key player in chronic inflammatory Type 1 and autoimmune diabetes

Interleukin-35: A key player in chronic inflammatory Type 1 and autoimmune diabetes

The Role of Regulatory T cells (Tregs) in Tumorigenesis: A Comprehensive Literature Review

The Relationship between TNF-a, IL-35, VEGF and Cutaneous Microvascular Dysfunction in Young Patients with Uncomplicated Type 1 Diabetes

Contact Info

Product

Resources

About